Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.76 |
| ▸ | SRC | P12931 | 7/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | CSK | P41240 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032760 | 0.94 | EGFR (0.87) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4032117 | 0.92 | EGFR (0.78) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4034534 | 0.91 | EGFR (0.73) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4036941 | 0.91 | EGFR (0.77) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4040534 | 0.91 | EGFR (0.80) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4034424 | 0.91 | EGFR (0.84) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4040545 | 0.90 | EGFR (0.81) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4037159 | 0.90 | EGFR (0.85) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4041510 | 0.89 | EGFR (0.84) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4037323 | 0.89 | EGFR (0.89) | EGFRSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| CN-1764651-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |